A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF

Key

Inclusion Criteria:

- Diagnosis of rheumatoid arthritis (functional class I - III) at least 6 months prior
to baseline

- Methotrexate (10 mg/week to 25 mg/week) > 3 months prior to Day 0 (stable dose > 4
weeks prior to Day 0)

- Must have had an inadequate response to anti-TNF therapy due to inadequate efficacy

Key Exclusion Criteria:

Medical History

- Serious local infection or systemic infection within 3 months of Day 0

- History (Hx) of recurrent infections requiring oral or parental anti-infective
treatment

- Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the
screening period

Laboratory Tests

- Clinically significant lab tests at screening; or

- Positive for hepatitis C antibody or hepatitis B at screening